Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
Andrew J Yee, Noopur S RajeDivision of Hematology-Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USAAbstract: Bone loss is a common side effect of cancer treatments, especially antihormonal treatments used in the treatment of breast and prostate cancer. Denosumab is a monoclonal...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Dove Medical Press
2012
|
| Subjects: | |
| Online Access: | https://doaj.org/article/e634a06fd60f46699b3fc6394d02c27f |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|